[NuvaRing-combined contraceptive vaginal ring: state of art in 2008. Expert Board of Polish Gynecological Society].
The development of steroid-releasing vaginal rings over the past three decades is reviewed to illustrate the role of this device as an effective hormonal contraceptive for women. NuvaRing is a combined contraceptive vaginal ring that releases constant low doses of ethinylestradiol and etonogestrel. The soft flexible combined ring is inserted in the vagina for three weeks and removed for seven days to allow withdrawal bleeding with no serious side-effects. Maximum levels of EE and ENG with NuvaRing were 30% and 40%, respectively, of those seen with the COC. Because ENG bioavailability was higher following vaginal administration, the systemic progestogen exposures were comparable with the oral contraceptives. NuvaRing has been shown to be safe and effective, with high levels of user compliance, acceptance and patient satisfaction.
Debski
Romuald
R
Kotarski
Jan
J
Paszkowski
Tomasz
T
Pawelczyk
Leszek
L
Skrzypulec
Violetta
V
Tomaszewski
Jacek
J
D003267:Contraception / Q000379:methods*; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D017135:Desogestrel / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006176:Gynecology / Q000592:standards; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000639:trends; D012252:Natural Family Planning Methods / Q000379:methods*; D009774:Obstetrics / Q000592:standards; D010353:Patient Education as Topic; D011044:Poland / Q000453:epidemiology; D011247:Pregnancy; D049168:Pregnancy, Unplanned; D016387:Women's Health
D003271:Contraceptive Agents, Female; D004338:Drug Combinations; C516519:NuvaRing; D004997:Ethinyl Estradiol; D017135:Desogestrel